Physician profile
Visal Pok
NPI 1457487217
$8,748.32
in general payments reported to CMS, 2019-2025
52 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $910 · 2021: $1,804 · 2022: $1,324 · 2023: $1,642 · 2024: $965 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,128.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,103.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $930.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $847.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.80 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $389.94 | 2019-2024 | Prolia, Evenity, Otezla |
| Amarin Pharma, INC. | $350.74 | 2019-2022 | |
| Lilly USA, LLC | $345.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $288.28 | 2019-2022 | |
| Corium, LLC | $279.19 | 2022-2024 | Azstarys |
| Astellas Pharma US INC | $222.74 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $180.35 | 2019-2023 | Rotateq, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $154.68 | 2021-2024 | Qelbree |
| Dexcom, INC. | $148.52 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $143.75 | 2024-2025 | Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Visal Pok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.